Want to see TSE:HBP full AI Analyst Report?
Helix BioPharma (HBP) Ratios
Helix BioPharma Ratios
TSE:HBP's free cash flow for Q3 2026 was $-880.00K. For the 2026 fiscal year, TSE:HBP's free cash flow was increased by $0.00 and operating cash flow was $-880.00K. See a summary of the company’s cash flow.
| Ratios | Jul 25 | Jul 24 | Jul 23 | Oct 22 | Oct 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.13 | 0.92 | 0.53 | 1.08 | 1.04 |
| Quick Ratio | 0.13 | 0.92 | 0.53 | 1.04 | 1.04 |
| Cash Ratio | 0.02 | 0.68 | 0.43 | 0.95 | 0.92 |
| Solvency Ratio | -1.62 | -5.86 | -3.35 | -1.78 | -1.42 |
| Operating Cash Flow Ratio | -1.19 | -3.31 | -2.95 | -1.91 | -2.40 |
| Short-Term Operating Cash Flow Coverage | -11.44 | 0.00 | 0.00 | -2.64 | -4.59 |
| Net Current Asset Value | $ -2.81M | $ -123.00K | $ -877.00K | $ 284.00K | $ -1.44M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.00 | 0.00 | 0.66 | 0.89 |
| Debt-to-Equity Ratio | 0.02 | 0.00 | 0.00 | 7.74 | -2.59 |
| Debt-to-Capital Ratio | 0.02 | 0.00 | 0.00 | 0.89 | 1.63 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 8.29 |
| Financial Leverage Ratio | 1.21 | -16.54 | -1.22 | 11.69 | -2.92 |
| Debt Service Coverage Ratio | -15.03 | -1320.43 | -451.93 | -2.23 | -3.82 |
| Interest Coverage Ratio | -542.50 | -1338.71 | -448.50 | -363.17 | -640.73 |
| Debt to Market Cap | 0.01 | 0.00 | 0.00 | 0.09 | 0.03 |
| Interest Debt Per Share | 0.01 | 0.00 | 0.00 | 0.08 | 0.13 |
| Net Debt to EBITDA | -0.05 | 0.12 | 0.13 | 0.13 | -0.00 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 99.46% | 98.60% | 100.00% | 92.63% | 82.63% |
| EBT Per EBIT | 96.46% | 100.27% | 100.18% | 100.41% | 99.62% |
| Return on Assets (ROA) | -27.68% | -622.16% | -611.27% | -163.00% | -194.61% |
| Return on Equity (ROE) | -33.40% | 10293.33% | 745.26% | -1905.96% | 567.91% |
| Return on Capital Employed (ROCE) | -34.81% | 10412.22% | 743.08% | -2049.22% | -5031.94% |
| Return on Invested Capital (ROIC) | -33.89% | 10265.95% | 743.08% | -217.26% | -357.89% |
| Return on Tangible Assets | -1260.29% | -622.58% | -611.27% | -163.00% | -194.61% |
| Earnings Yield | -8.73% | -18.11% | -15.50% | -21.41% | -6.91% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.02 | 0.03 | 0.02 | 0.12 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.07 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -84059.50 | -22291.07 | -13841.92 | -13231.25 | -3093.01 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 4988.33 | 0.00 |
| Days of Payables Outstanding | 84059.50 | 22291.07 | 13841.92 | 18219.58 | 3093.01 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 4988.33 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.07 | -0.12 | -0.14 | -0.22 | -0.34 |
| Free Cash Flow Per Share | -0.07 | -0.12 | -0.14 | -0.22 | -0.34 |
| Dividend Paid and CapEx Coverage Ratio | -1915.50 | -372.79 | -552.70 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | -1915.50 | -372.79 | -552.70 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -11.40 | 0.00 | 0.00 | -2.64 | -2.58 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -6.43% | -10.23% | -13.65% | -22.92% | -8.13% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -11.46 | -5.52 | -6.45 | -4.67 | -14.47 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 3.83 | -568.43 | -48.08 | 89.04 | -82.16 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -15.56 | -9.78 | -7.33 | -4.36 | -12.30 |
| Price-to-Operating Cash Flow Ratio | -15.57 | -9.80 | -7.34 | -4.36 | -12.30 |
| Price-to-Earnings Growth (PEG) Ratio | 0.21 | -0.19 | 0.32 | 0.16 | 0.78 |
| Enterprise Value Multiple | -11.49 | -5.34 | -6.30 | -4.58 | -12.10 |
| Enterprise Value | 59.91M | 50.08M | 39.77M | 27.62M | 114.49M |
| EV to EBITDA | -11.49 | -5.34 | -6.30 | -4.58 | -12.10 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -15.63 | -9.57 | -7.18 | -4.24 | -12.31 |
| EV to Operating Cash Flow | -15.64 | -9.60 | -7.20 | -4.24 | -12.31 |
| Tangible Book Value Per Share | -0.05 | -0.00 | -0.02 | 0.01 | -0.05 |
| Shareholders’ Equity Per Share | 0.28 | -0.00 | -0.02 | 0.01 | -0.05 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.01 | 0.01 | -0.00 | 0.07 | 0.17 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.09 | -0.21 | -0.16 | -0.20 | -0.29 |
| Tax Burden | 0.99 | 0.99 | 1.00 | 0.93 | 0.83 |
| Interest Burden | 1.00 | 1.00 | 0.99 | 1.00 | 0.99 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.74 | 0.56 | 0.88 | 0.99 | 1.16 |
Currency in CAD
